Paradigm Biopharmaceuticals (ASX:PAR) has announced it has received regulatory and ethics approval from the UK regulator for a key late-stage clinical trial.
The company is focused on repurposing existing molecules for new indications with an unmet clinical need.
It says the approvals mean it can now proceed with commencing activities in the UK for its global Phase 3 PARA_OA_002 clinical trial. It said it expects to imminently commence enrolling participants with knee osteoarthritis at five sites in the UK.
Paradigm chief medical officer and Interim CEO Dr Donna Skerrett said, “We are very pleased to have received the combined regulatory and ethics approval in the UK from the MHRA, which is another milestone, as we continue to progress with clinical site initiation of our phase 3 PARA_OA_002 study in Australia, the US and now in the UK”
